A promising new COVID-19 vaccine candidate developed by researchers at the Centenary Institute and the University of Sydney ...

Earlier this summer the FDA asked Moderna for more efficacy data on its flu vaccine before it could review an mRNA-based ...

The French pharma will pay $1.15 billion upfront to buy Vicebio and gain access to non-mRNA vaccine candidates against RSV, ...

A research team with Professor Neha Kamat used synthetic liposomes and bacterial extracts to generate immune responses ...

Researchers from Cornell and Northwestern universities have developed a rapid, cell-free method for building nanoparticle ...

AI also supports reverse vaccinology, where pathogen genomes are computationally analyzed to identify immunogenic regions ...

SHELTON, CT / ACCESS Newswire / July 21, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.: NNVC ) (the ...

Partial immunity from COVID in residents early in the pandemic and infection-prevention measures may explain the findings, ...

SHELTON, CONNECTICUT / ACCESS Newswire / July 16, 2025 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) ...

Much of the public distrust stems from false information around messenger RNA (mRNA) vaccines for COVID-19, even though they ...

Vinay Prasad overruled other reviewers for a third time in recent months in clearing only narrow use of Moderna's vaccine in ...